Biomagnification of polybrominated diphenyl ethers and alternative halogenated flame retardants through food chains of yellowfin tuna (Thunnus albacares) and their prey from the South China Sea and the associated potential health risk.

Polybrominated diphenyl ethers (PBDEs) and their alternative halogenated flame retardants (AHFRs) have gained global attention due to their ubiquitous occurrence, bioaccumulation, and toxic properties. However, the biomagnification of halogenated flame retardants (HFRs), particularly AHFRs, in various food chains is not yet well understood. In this study, yellowfin tuna (Thunnus albacares), along with its prey, flying squid (Sthenoteuthis oualaniensis) and round scad (Decapterus maruadsi), were sampled from the South China Sea (SCS) to investigate the biomagnification potential of PBDEs and AHFRs, including dechlorane plus (DP) and decabromodiphenyl ethane (DBDPE).

Evidence of polybrominated diphenyl ethers (PBDEs) and alternative halogenated flame retardants (AHFRs) in wild fish species from the remote tropical marine environment, south China sea.

Polybrominated diphenyl ethers (PBDEs) and their alternatives (e.g., dechlorane plus (DPs) and decabromodiphenyl ethane (DBDPE)) are ubiquitous in various environmental media.

Upregulation of miR‑132‑3p in cholangiocarcinoma tissues: A study based on RT‑qPCR, The Cancer Genome Atlas miRNA sequencing, Gene Expression Omnibus microarray data and bioinformatics analyses.

MicroRNAs (miRNAs/miRs) have been reported to be closely associated with numerous human diseases, including cholangiocarcinoma (CCA). However, the number of miRNAs known to be involved in CCA is limited, and the association between miR‑132‑3p and CCA remains unknown. In the present study, the clinical role of miR‑132‑3p and its potential signaling pathways were investigated by multiple approaches.

Construction of a model to predict the prognosis of patients with cholangiocarcinoma using alternative splicing events.

Cholangiocarcinoma (CCA) is a type of malignant tumor that originates in the mucosal epithelial cells of the biliary system. It is a highly aggressive cancer that progresses rapidly, has low surgical resection rates and a high recurrence. At present, no prognostic molecular biomarker for CCA has been identified.